School of Integrative Biological & Chemical Sciences Faculty Publications and Presentations
Document Type
Article
Publication Date
10-27-2025
Abstract
Gliomas, the most common primary brain tumors, present significant diagnostic and treatment challenges due to their infiltrative nature and heterogeneity. Our previous research revealed that glioma tumors in both animals and humans accumulate beta-amyloid protein (Aβ), detectable through immunohistochemical methods or staining with amyloid-specific dyes. We hypothesize that beta-amyloid-specific dyes could serve as glioma markers, potentially enabling the delineation of glioma tumors or targeted therapeutics delivery. In this study, the specificity and blood-brain barrier permeability of two fluorescent beta-amyloid-specific dyes, Brilliant Blue G (BBG) and BODIPY-based Amyloid Probe-1 (BAP-1), were evaluated in C57Bl/6 mouse glioma implantation models using GL261 and KR158 glioma cells. The findings demonstrate that both BBG and BAP-1 selectively stain gliomas, providing a clear contrast from normal brain tissue. The study results open avenues for further development of glioma visualization methods and targeted therapeutic delivery strategies for clinical applications.
Recommended Citation
Kucheryavykh, Lilia, Jescelica Ortiz Rivera, Boris Ermolinsky, Vassiliy Tsytsarev, Lynnette Cary, Janaina Alves, Adriana Reyes et al. "Targeting Gliomas with Beta-Amyloid-Specific Dyes: A Novel Approach for In Vivo Staining and Potential Therapeutic Applications." International Journal of Molecular Sciences 26, no. 21 (2025): 10450. https://doi.org/10.3390/ijms262110450
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Publication Title
International Journal of Molecular Sciences
DOI
10.3390/ijms262110450

Comments
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).